Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Model-Informed Drug Development for Malaria Therapeutics.

Kayla Ann Andrews1,2, David Wesche3, James McCarthy4,5

  • 1Cognigen Corporation, a subsidiary of Simulations Plus, Buffalo, New York 14221, USA; email: Kayla.Andrews@cognigencorp.com , Luann.Phillips@cognigencorp.com , grasela@cognigencorp.com.

Annual Review of Pharmacology and Toxicology
|October 10, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers.

British journal of clinical pharmacology·2026
Same author

Safety, tolerability and pharmacokinetic properties of intranasal artesunate in a first in human phase 1 trial.

Scientific reports·2026
Same author

Effects of a policy intended to reduce vasopressin use in intensive care unit patients with shock.

Journal of critical care·2026
Same author

Shared urinary metabolomic signatures as potential biomarkers for early intestinal <i>Schistosoma</i> infection across multiple species.

Current research in parasitology & vector-borne diseases·2026
Same author

Population Pharmacokinetics and Pharmacodynamics of Paracetamol in Malaysian Patients With Plasmodium knowlesi Malaria.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Characterising the circulation of gametocytes and mosquito infectivity in induced blood stage malaria.

The Journal of infectious diseases·2026
This summary is machine-generated.

Developing new malaria treatments is crucial due to drug resistance. A comprehensive disease-drug model integrating preclinical and clinical data can accelerate the discovery of effective malaria therapeutics.

Area of Science:

  • Malariology
  • Pharmacology
  • Computational Biology

Background:

  • Malaria remains a significant global health challenge, causing widespread illness and death, especially in developing nations.
  • Increasing resistance to existing antimalarial drugs necessitates urgent development of novel therapeutic strategies.
  • Current drug development relies on in vitro and in vivo experiments, which can be time-consuming and resource-intensive.

Purpose of the Study:

  • To propose the development of a comprehensive disease-drug model for malaria.
  • To highlight the potential of integrating diverse preclinical and clinical data within a unified modeling framework.
  • To underscore the need for accelerated drug development pipelines for new antimalarial compounds.

Main Methods:

  • Review of advancements in in vitro and in vivo experimental methodologies for malaria drug discovery.
Keywords:
controlled human malaria infectiondisease-drug modelmalariamodel-informed drug developmentpharmacodynamicspharmacokinetics

Related Experiment Videos

  • Conceptualization of a disease-drug model integrating data from various stages of drug development.
  • Discussion of the potential impact of such a model on traditional clinical development processes.

    • Main Results:

    • Significant progress has been made in experimental techniques generating valuable data for compound evaluation.
    • A comprehensive disease-drug model offers a pathway to synthesize and leverage this data effectively.
    • Such a model could streamline decision-making throughout the drug development lifecycle.

    Conclusions:

    • A unified disease-drug model is essential for accelerating the development of new malaria therapies.
    • Integrating diverse data sources can enhance the efficiency and reduce the cost of antimalarial drug discovery.
    • This approach promises to significantly impact the traditional, lengthy clinical development process for malaria drugs.